Schwartz M S, Cappell M S
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
Dig Dis Sci. 1989 Oct;34(10):1617-20. doi: 10.1007/BF01537122.
Two patients without risk factors or a prior history of pancreatitis developed acute pancreatitis soon after initiating pentamidine isethionate therapy for Pneumocystis carinii pneumonia associated with the acquired immunodeficiency syndrome. In both patients the pancreatitis improved following medication cessation. One patient did not redevelop pancreatitis when he subsequently received inhaled pentamidine. Review of the literature revealed five previously reported cases of this drug reaction. Pentamidine-associated pancreatitis appears to develop within three weeks of initiating therapy and after receiving more than 1 g in cumulative dosage. Glucose abnormalities, renal insufficiency, and non-specific abdominal pain may be early warning signs of pentamidine-associated pancreatitis.
两名无胰腺炎危险因素或既往病史的患者，在开始使用乙磺半胱氨酸喷他脒治疗与获得性免疫缺陷综合征相关的卡氏肺孢子虫肺炎后不久，就发生了急性胰腺炎。两名患者在停药后胰腺炎均有所改善。其中一名患者后来吸入喷他脒时未再次发生胰腺炎。文献回顾发现了五例先前报道的这种药物反应病例。喷他脒相关的胰腺炎似乎在开始治疗后三周内以及累积剂量超过1克后发生。血糖异常、肾功能不全和非特异性腹痛可能是喷他脒相关胰腺炎的早期预警信号。
